301263 泰恩康
已收盘 06-18 15:00:00
资讯
新帖
简况
泰恩康(301263)披露回购公司股份方案公告,6月17日股价下跌1.72%
证券之星 · 06-17 17:35
泰恩康(301263)披露回购公司股份方案公告,6月17日股价下跌1.72%
泰恩康(301263.SZ)拟1亿元至2亿元回购公司股份
智通财经 · 06-16
泰恩康(301263.SZ)拟1亿元至2亿元回购公司股份
6月8日泰恩康跌5.71%,大成积极成长混合A基金重仓该股
证券之星 · 06-08
6月8日泰恩康跌5.71%,大成积极成长混合A基金重仓该股
泰恩康最新公告:控股股东提议1亿至2亿元回购公司股份
证券之星 · 06-04
泰恩康最新公告:控股股东提议1亿至2亿元回购公司股份
6月4日泰恩康跌5.05%,大成积极成长混合A基金重仓该股
证券之星 · 06-04
6月4日泰恩康跌5.05%,大成积极成长混合A基金重仓该股
泰恩康:玫瑰痤疮适应症目前已完成IIa期全部受试者入组并启动IIb期临床试验
证券之星 · 06-04
泰恩康:玫瑰痤疮适应症目前已完成IIa期全部受试者入组并启动IIb期临床试验
泰恩康:抗衰老及阿尔兹海默症的研发经费未被纳入公司可转债募集资金使用方案
证券之星 · 06-04
泰恩康:抗衰老及阿尔兹海默症的研发经费未被纳入公司可转债募集资金使用方案
泰恩康:CKBA乳膏联合NB-UVB方案300例样本评估疗效与安全性
证券之星 · 06-04
泰恩康:CKBA乳膏联合NB-UVB方案300例样本评估疗效与安全性
6月3日泰恩康创60日新低,大成积极成长混合A基金重仓该股
证券之星 · 06-03
6月3日泰恩康创60日新低,大成积极成长混合A基金重仓该股
泰恩康(301263)披露控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组暨提前启动IIb期临床试验的公告,6月01日股价上涨0.28%
证券之星 · 06-01
泰恩康(301263)披露控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组暨提前启动IIb期临床试验的公告,6月01日股价上涨0.28%
医保局发布医保目录调整方案;内蒙古检查售卖集采药违规药店
21世纪经济报道 · 06-01
医保局发布医保目录调整方案;内蒙古检查售卖集采药违规药店
泰恩康最新公告:控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成入组并提前启动IIb期
证券之星 · 05-31
泰恩康最新公告:控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成入组并提前启动IIb期
泰恩康最新公告:控股子公司CKBA乳膏儿童白癜风适应症II期临床试验完成首例受试者入组
证券之星 · 05-29
泰恩康最新公告:控股子公司CKBA乳膏儿童白癜风适应症II期临床试验完成首例受试者入组
泰恩康(301263)披露2025年年度股东会决议公告,5月21日股价下跌0.11%
证券之星 · 05-21
泰恩康(301263)披露2025年年度股东会决议公告,5月21日股价下跌0.11%
泰恩康(301263.SZ)子公司收到和胃整肠丸药品注册证书
智通财经 · 05-21
泰恩康(301263.SZ)子公司收到和胃整肠丸药品注册证书
泰恩康拟募资8.7亿谋转型
中国经营网 · 05-16
泰恩康拟募资8.7亿谋转型
泰恩康(301263)披露召开2025年年度股东会提示性公告,5月15日股价下跌0.41%
证券之星 · 05-15
泰恩康(301263)披露召开2025年年度股东会提示性公告,5月15日股价下跌0.41%
泰恩康拟发行可转债募资不超过8.7亿元 用于项目投资
美股速递 · 05-08
泰恩康拟发行可转债募资不超过8.7亿元 用于项目投资
泰恩康最新公告:拟发行不超8.7亿元可转债用于创新药等项目
证券之星 · 05-08
泰恩康最新公告:拟发行不超8.7亿元可转债用于创新药等项目
每周股票复盘:泰恩康(301263)CKBA儿童白癜风II期临床将首例入组
证券之星 · 05-03
每周股票复盘:泰恩康(301263)CKBA儿童白癜风II期临床将首例入组
加载更多
公司概况
公司名称:
广东泰恩康医药股份有限公司
所属行业:
批发业
上市日期:
2022-03-29
主营业务:
广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药,2020年8月正式投放市场,目前在达泊西汀院外渠道市场稳居头部地位,尤其在线下零售市场形成显著品牌优势。
发行价格:
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":20.27,"timestamp":1781766222000,"preClose":19.38,"halted":0,"volume":8130952,"delay":0,"changeRate":0.0459,"floatShares":364000000,"shares":511000000,"eps":0.0503,"marketStatus":"已收盘","change":0.89,"latestTime":"06-18 15:00:00","open":19.39,"high":20.6,"low":19.18,"amount":164000000,"amplitude":0.0733,"askPrice":20.28,"askSize":100,"bidPrice":20.27,"bidSize":236,"shortable":0,"etf":0,"ttmEps":0.0503,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.38,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":21.32,"lowLimit":17.44,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":510597000,"isCdr":false,"pbRate":5.83,"roa":"--","peRate":402.982107,"roe":"1.7%","epsLYR":0.07,"committee":0.226601,"marketValue":10350000000,"turnoverRate":0.0223,"status":0,"floatMarketCap":7384000000},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2644717868","title":"泰恩康(301263)披露回购公司股份方案公告,6月17日股价下跌1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644717868","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644717868?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:35","pubTimestamp":1781688951,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,泰恩康报收于19.38元,较前一交易日下跌1.72%,最新总市值为98.95亿元。本次回购股份旨在维护公司价值及股东权益,回购期限为董事会审议通过之日起不超过3个月。预计回购股份数量为286.53万股至573.07万股,占公司总股本的0.56%至1.12%。回购股份将在披露回购结果后十二个月后出售,并在三年内完成出售,未能出售的将依法注销。本次回购不会影响公司正常经营和持续上市地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643512753","title":"泰恩康(301263.SZ)拟1亿元至2亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2643512753","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643512753?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:51","pubTimestamp":1781603487,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康(301263.SZ)发布公告,公司拟使用自有资金和自筹资金以集中竞价交易方式回购公司A股股份,用于维护公司价值及股东权益所必需,回购股份的资金总额不低于人民币1亿元且不超过人民币2亿元(均包含本数),回购股份的价不超过人民币34.90元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100964","title":"6月8日泰恩康跌5.71%,大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100964?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:06","pubTimestamp":1780909604,"startTime":"0","endTime":"0","summary":"证券之星消息,6月8日泰恩康跌5.71%创60日新低,收盘报18.51元,换手率2.46%,成交量8.96万手,成交额1.68亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元,最新净值1.243,较上一交易日下跌2.97%,近一年上涨48.86%。大成积极成长混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640152991","title":"泰恩康最新公告:控股股东提议1亿至2亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152991","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640152991?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:50","pubTimestamp":1780573811,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司收到控股股东、实际控制人、董事长郑汉杰提议,拟使用自有资金和自筹资金以集中竞价交易方式回购公司股份,回购资金总额不低于1亿元且不超过2亿元,回购价格上限不高于董事会审议通过前三十个交易日股票交易均价的150%,回购期限为董事会审议通过后三个月内。回购股份将用于维护公司价值及股东权益,并在披露结果后12个月后出售或三年内未使用部分予以注销。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400037356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153426","title":"6月4日泰恩康跌5.05%,大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640153426?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:46","pubTimestamp":1780562808,"startTime":"0","endTime":"0","summary":"证券之星消息,6月4日泰恩康跌5.05%创60日新低,收盘报18.81元,换手率2.05%,成交量7.48万手,成交额1.43亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元,最新净值1.279,较上一交易日上涨0.24%,近一年上涨55.8%。大成积极成长混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400028762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133962","title":"泰恩康:玫瑰痤疮适应症目前已完成IIa期全部受试者入组并启动IIb期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133962?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:12","pubTimestamp":1780535525,"startTime":"0","endTime":"0","summary":"证券之星消息,泰恩康(301263)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问下ckba治疗玫瑰痤疮2b期方案入组人数和时间和2a期一样还是有其他变化?顺利的话预计多久能读出数据并进入3期?泰恩康回复:您好,玫瑰痤疮适应症目前已完成IIa期全部受试者入组并启动IIb期临床试验,目标2027年上半年完成II期、下半年进入III期。感谢您对公司的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133612","title":"泰恩康:抗衰老及阿尔兹海默症的研发经费未被纳入公司可转债募集资金使用方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133612?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:09","pubTimestamp":1780535365,"startTime":"0","endTime":"0","summary":"根据公司2026年5月披露的可转债募集资金使用可行性分析报告中,创新药研发项目主要聚焦CKBA系列三个品种的临床研究,抗衰老及阿尔兹海默症的研发经费未被纳入公司可转债募集资金使用方案,若后续有调整,公司将及时履行信息披露义务,请您关注公司后续发布的可转债方案相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640413351","title":"泰恩康:CKBA乳膏联合NB-UVB方案300例样本评估疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640413351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640413351?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:06","pubTimestamp":1780535190,"startTime":"0","endTime":"0","summary":"证券之星消息,泰恩康06月03日在投资者关系平台上答复投资者关心的问题。泰恩康回复:您好,公司于2026年5月29日完成CKBA乳膏儿童白癜风II期临床试验首例受试者入组,其他受试者招募和筛选工作正在加快推进。目前国内儿童白癜风治疗手段有限,公司采用CKBA 乳膏联合窄谱中波紫外线 方案,300例样本可充分评估联合疗法在儿童中的疗效持续性与安全性,为后续III期临床试验提供高质量数据支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640797763","title":"6月3日泰恩康创60日新低,大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640797763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640797763?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:42","pubTimestamp":1780476143,"startTime":"0","endTime":"0","summary":"证券之星消息,6月3日泰恩康创60日新低,收盘报19.81元,当日跌2.37%,换手率1.4%,成交量5.08万手,成交额1.02亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元,最新净值1.276,较上一交易日上涨3.32%,近一年上涨55.8%。大成积极成长混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640057958","title":"泰恩康(301263)披露控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组暨提前启动IIb期临床试验的公告,6月01日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640057958","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640057958?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:18","pubTimestamp":1780309118,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘,泰恩康报收于21.11元,较前一交易日上涨0.28%,最新总市值为107.79亿元。公告显示,公司控股子公司江苏博创园生物医药科技有限公司自主研发的1类创新药CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组,获得初步积极有效的试验数据。IIa期临床试验为单中心、开放性、单臂设计,计划入组15例,已全部完成。目前IIb期临床试验方案已制定,研究机构初步筛选完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981365","title":"医保局发布医保目录调整方案;内蒙古检查售卖集采药违规药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981365","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981365?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272073,"startTime":"0","endTime":"0","summary":"药械审批国家医保局发布2026年国家医保目录调整工作方案5月31日,国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755285483.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755285483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","300562","BK0250","BK0201","600513","BK0109","BK0060","BK0239","BK0196","BK0183","BK0216","301096","BK0096","BK0028","BK0175","301263","BK0187","600521","BK0114","IPOS","BK0185","BK0251","BK0070","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639160059","title":"泰恩康最新公告:控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成入组并提前启动IIb期","url":"https://stock-news.laohu8.com/highlight/detail?id=2639160059","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639160059?lang=zh_cn&edition=full","pubTime":"2026-05-31 16:20","pubTimestamp":1780215640,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司控股子公司博创园自主研发的1类创新药CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组,获得积极有效的初步试验数据,公司拟提前启动IIb期临床试验。IIa期试验初步结果显示,已完成4周随访的受试者炎性皮损计数显著减少,无严重不良反应发生。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100004981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626760","title":"泰恩康最新公告:控股子公司CKBA乳膏儿童白癜风适应症II期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626760","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626760?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:58","pubTimestamp":1780048706,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司控股子公司博创园组织开展的CKBA乳膏联合窄谱中波紫外线在2-12岁儿童非节段型白癜风受试者中的II期临床试验完成首例受试者入组。该药品为化学药品1类创新药,适应症为2-12岁儿童非节段型白癜风,主要试验机构为杭州市第三人民医院。目前全球无获批产品用于儿童白癜风治疗,CKBA乳膏有望填补这一空白。该项目不会对公司近期业绩产生重大影响,但存在研发及审批不确定性风险。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900034039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637938285","title":"泰恩康(301263)披露2025年年度股东会决议公告,5月21日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637938285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637938285?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:16","pubTimestamp":1779358579,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,泰恩康报收于26.43元,较前一交易日下跌0.11%,最新总市值为112.46亿元。公司于近日披露《2025年年度股东会决议公告》。公告显示,广东泰恩康医药股份有限公司于2026年5月20日召开2025年年度股东会,审议通过了《2025年度董事会工作报告》《2025年年度报告》及其摘要、2025年度利润分配及资本公积金转增股本预案、续聘2026年度审计机构、为子公司提供担保额度预计、变更注册资本并修订公司章程等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637383351","title":"泰恩康(301263.SZ)子公司收到和胃整肠丸药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637383351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637383351?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:00","pubTimestamp":1779350421,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康 发布公告,公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局签发的和胃整肠丸《药品注册证书》。2023年7月,公司与泰国李万山药厂两合公司签订《技术转让合同》,由此取得“和胃整肠丸”的全套生产技术及在国内的所有权益。此次“和胃整肠丸”同名同方药注册申请经国家药监局审批通过,标志着该品种的国产化进程顺利落地,“和胃整肠丸”成为公司自有独家品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635305100","title":"泰恩康拟募资8.7亿谋转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2635305100","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635305100?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:16","pubTimestamp":1778876179,"startTime":"0","endTime":"0","summary":"“泰恩康目前研发需要大量资金,公司有没有融资计划?”5月7日,有投资者在泰恩康(301263.SZ)业绩会上抛出上述问题后,5月8日,泰恩康披露向不特定对象发行可转换公司债券预案,公司拟募资8.7亿元,用于创新药研发、创新药及高端外用制剂产业化建设等四个项目。其中,创新药研发项目拟投入3.51亿元,金额占比最高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605163739368347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033110","title":"泰恩康(301263)披露召开2025年年度股东会提示性公告,5月15日股价下跌0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635033110?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:36","pubTimestamp":1778855781,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,泰恩康报收于26.9元,较前一交易日下跌0.41%,最新总市值为114.46亿元。该股当日开盘27.01元,最高27.38元,最低26.74元,成交额达9724.86万元,换手率为1.18%。公司于近日发布《关于召开2025年年度股东会的提示性公告》。公告显示,广东泰恩康医药股份有限公司将于2026年5月20日召开2025年年度股东会,会议采取现场表决与网络投票相结合的方式。股权登记日为2026年5月14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500044302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195482505","title":"泰恩康拟发行可转债募资不超过8.7亿元 用于项目投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1195482505","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195482505?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:51","pubTimestamp":1778244707,"startTime":"0","endTime":"0","summary":"广东泰恩康医药股份有限公司宣布,计划通过发行可转换公司债券筹集资金,最高募资额不超过8.7亿元人民币。此次募集资金将专项用于支持公司相关项目的发展建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633471459","title":"泰恩康最新公告:拟发行不超8.7亿元可转债用于创新药等项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2633471459","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633471459?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:50","pubTimestamp":1778244659,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司拟向不特定对象发行可转换公司债券,募集资金总额不超过8.7亿元(含本数),扣除发行费用后拟用于创新药研发项目、创新药及高端外用制剂产业化建设项目、华铂凯盛制剂生产基地项目及亳州泰恩康现代中药制剂产线建设项目(一期)。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800041117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","159992","BK0250","301263","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632231608","title":"每周股票复盘:泰恩康(301263)CKBA儿童白癜风II期临床将首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2632231608","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632231608?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:34","pubTimestamp":1777768451,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,泰恩康报收于28.85元,较上周的28.53元上涨1.12%。本周关注点来自机构调研要点:儿童白癜风2-12岁适应症II期临床预计2026年上半年完成首例入组。②儿童白癜风2-12岁适应症II期临床试验已通过伦理审核,预计2026年上半年完成首例入组,目标2027年下半年读出数据。CKB乳膏已取得国内首张 2-12岁儿童非节段型白癜风 II期临床试验批件,短期内市场处于空白状态,公司有望成为首个获批儿童白癜风外用药物的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781905031503,"stockEarnings":[{"period":"1week","weight":0.0957},{"period":"1month","weight":-0.1},{"period":"3month","weight":-0.0751},{"period":"6month","weight":-0.1208},{"period":"1year","weight":-0.2966},{"period":"ytd","weight":-0.1593}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"12996人(较上一季度减少0.84%)","perCapita":"28031股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"51059万元","survey":" 广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药,2020年8月正式投放市场,目前在达泊西汀院外渠道市场稳居头部地位,尤其在线下零售市场形成显著品牌优势。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}